Literature DB >> 18455870

Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology.

Saila Vepsäläinen1, Mikko Hiltunen, Seppo Helisalmi, Jun Wang, Thomas van Groen, Heikki Tanila, Hilkka Soininen.   

Abstract

Expression levels of amyloid beta (Abeta)-degrading enzymes, insulin degrading enzyme (IDE) and neprilysin (NEP), were examined in transgenic mice with Alzheimer's disease-like neuropathology. After the development of first Abeta plaques in transgenic mice brain, cortical mRNA and protein levels of IDE were significantly up-regulated in the transgenic mice compared to their non-transgenic littermates. Up-regulation of IDE mRNA-levels occurred in parallel with increased Abeta40 and Abeta42 production. Additionally, a significant positive correlation was observed between protein levels of IDE and full-length amyloid precursor protein (APP) in the cerebral cortex. mRNA and protein levels of NEP were also nominally up-regulated in Tg mice compared to controls. These data may reflect up-regulation of the IDE and possibly of NEP expression in response to the Abeta accumulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455870     DOI: 10.1016/j.neulet.2008.04.025

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

1.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.

Authors:  Robert J Baranello; Krishna L Bharani; Vasudevaraju Padmaraju; Nipun Chopra; Debomoy K Lahiri; Nigel H Greig; Miguel A Pappolla; Kumar Sambamurti
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

2.  Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.

Authors:  Suqing Wang; Rui Wang; Lang Chen; David A Bennett; Dennis W Dickson; Deng-Shun Wang
Journal:  J Neurochem       Date:  2010-07-30       Impact factor: 5.372

3.  Sustained high body temperature exacerbates cognitive function and Alzheimer's disease-related pathologies.

Authors:  Cha-Gyun Jung; Reiko Kato; Chunyu Zhou; Mona Abdelhamid; Esraa Ibrahim A Shaaban; Hitoshi Yamashita; Makoto Michikawa
Journal:  Sci Rep       Date:  2022-07-18       Impact factor: 4.996

4.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

5.  Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology.

Authors:  Men Su; Kambiz Naderi; Nathalie Samson; Ihsen Youssef; Livia Fülöp; Zsolt Bozso; Serge Laroche; Benoit Delatour; Sabrina Davis
Journal:  Mol Neurobiol       Date:  2019-01-25       Impact factor: 5.590

6.  Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta.

Authors:  Jennifer C Palmer; Shabnam Baig; Patrick G Kehoe; Seth Love
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

7.  Cholesterol-enriched diet causes age-related macular degeneration-like pathology in rabbit retina.

Authors:  Bhanu Dasari; Jaya Rp Prasanthi; Gurdeep Marwarha; Brij B Singh; Othman Ghribi
Journal:  BMC Ophthalmol       Date:  2011-08-18       Impact factor: 2.209

8.  Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease.

Authors:  L Arab; R Sadeghi; D G Walker; L-F Lue; M N Sabbagh
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

9.  Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis.

Authors:  Suzhen Dong; Yale Duan; Yinghe Hu; Zheng Zhao
Journal:  Transl Neurodegener       Date:  2012-09-21       Impact factor: 8.014

10.  Ginsenoside Rg1 decreases Aβ(1-42) level by upregulating PPARγ and IDE expression in the hippocampus of a rat model of Alzheimer's disease.

Authors:  QianKun Quan; Jue Wang; Xi Li; Yi Wang
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.